GlaxoSmithKline - Further extension of product portfolio in the Middle East and North Africa

List of all recent work 

Slaughter and May advised GlaxoSmithKline plc (GSK), one of the world’s leading research-based pharmaceutical and healthcare companies, supporting GSK’s in-house team, on the acquisition of the branded generics business of Bristol Myers Squibb (BMS) in Lebanon, Jordon, Syria, Libya and Yemen for $23.2 million (£14.2 million) in cash. The business comprises a portfolio of 13 branded pharmaceuticals.  

This purchase, which was announced on 2 July 2009, is another step forward in GSK’s strategy to accelerate growth in emerging markets and signals a strong commitment to provide quality medicines to patients in the Middle East and North Africa.

David Johnson (partner), Harry Coghill (associate); Intellectual Property: Susie Middlemiss (partner), Laura Hillier (associate)

GlaxoSmithKline: Steven Rix